These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [The treatment of Gaucher's disease in The Netherlands using enzyme substitution therapy]. Hollak CE; van Oers MH; Maaswinkel P; Aerts JM; Goudsmit R Ned Tijdschr Geneeskd; 1996 May; 140(19):1011-3. PubMed ID: 8684492 [No Abstract] [Full Text] [Related]
24. Total glycolipid and glucosylceramide content in serum and urine of patients with Gaucher's disease type 3 before and after enzyme replacement therapy. Gornati R; Bembi B; Tong X; Boscolo R; Berra B Clin Chim Acta; 1998 Mar; 271(2):151-61. PubMed ID: 9565330 [TBL] [Abstract][Full Text] [Related]
25. Imiglucerase treatment in Gaucher's disease. Shah U; Nadeem N; Husen Y; Fadoo Z J Ayub Med Coll Abbottabad; 2007; 19(2):56-9. PubMed ID: 18183722 [TBL] [Abstract][Full Text] [Related]
26. [Clinical outcomes of 2 pediatric patients with Gaucher's disease in enzyme replacement therapy for 9 years]. Quijada Fraile P; Martín Hernández E; Teresa García-Silva M Med Clin (Barc); 2011 Sep; 137 Suppl 1():43-5. PubMed ID: 22230125 [TBL] [Abstract][Full Text] [Related]
27. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. Altarescu G; Hill S; Wiggs E; Jeffries N; Kreps C; Parker CC; Brady RO; Barton NW; Schiffmann R J Pediatr; 2001 Apr; 138(4):539-47. PubMed ID: 11295718 [TBL] [Abstract][Full Text] [Related]
28. [Enzyme therapy of Gaucher's disease]. Beck M Dtsch Med Wochenschr; 1993 Jun; 118(25):964-5. PubMed ID: 8519225 [No Abstract] [Full Text] [Related]
35. [Type I Gaucher's disease: clinical, evolutive and therapeutic features in 8 cases]. Giraldo P; Pérez-Calvo J; Cortés T; Civeira F; Rubio-Félix D Sangre (Barc); 1994 Feb; 39(1):3-7. PubMed ID: 8197516 [TBL] [Abstract][Full Text] [Related]
36. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. Barton NW; Brady RO; Dambrosia JM; Di Bisceglie AM; Doppelt SH; Hill SC; Mankin HJ; Murray GJ; Parker RI; Argoff CE N Engl J Med; 1991 May; 324(21):1464-70. PubMed ID: 2023606 [TBL] [Abstract][Full Text] [Related]
37. [Persistence of pulmonary lesions in a 6-year-old boy with type I Gaucher's disease treated by alglucerase since the age of 20 months]. Versteegh C; Avni F; Cuvelier P; Ferster A Arch Pediatr; 1998 Dec; 5(12):1341-3. PubMed ID: 9885741 [TBL] [Abstract][Full Text] [Related]
38. [Safety of use of velaglucerase in 2 patients with type 1 Gaucher's disease]. Latre P; Giraldo P Med Clin (Barc); 2011 Sep; 137 Suppl 1():39-42. PubMed ID: 22230124 [TBL] [Abstract][Full Text] [Related]
39. [Analysis of the densitometric method of hand bone radiograms and assessment of early changes of bone structure in the children with Gaucher's disease on enzyme replacement therapy (ERT)]. Łyson-Wojciechowska G; Skawiński W; Tylki-Szymańska A Pediatr Endocrinol Diabetes Metab; 2007; 13(4):218-223. PubMed ID: 18183671 [TBL] [Abstract][Full Text] [Related]
40. Pulmonary hypertension in Gaucher's disease. Pastores GM; Miller A Lancet; 1998 Aug; 352(9127):580. PubMed ID: 9716094 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]